[go: up one dir, main page]

BR0111210A - Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias - Google Patents

Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias

Info

Publication number
BR0111210A
BR0111210A BR0111210-4A BR0111210A BR0111210A BR 0111210 A BR0111210 A BR 0111210A BR 0111210 A BR0111210 A BR 0111210A BR 0111210 A BR0111210 A BR 0111210A
Authority
BR
Brazil
Prior art keywords
osteoporosis
joint disease
prevention
treatment
composition
Prior art date
Application number
BR0111210-4A
Other languages
English (en)
Inventor
Herwig Buchholz
Jerzy Meduski
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0111210A publication Critical patent/BR0111210A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO PARA O TRATAMENTO E/OU PREVENçãO DE OSTEOPOROSE E/OU DOENçAS DE JUNTAS INFLAMATóRIAS". Composições e composições farmacêuticas são descritas que compreendem: um componente A compreendendo um ou mais flavonol glicosídeos, um componente B compreendendo um ou mais compostos de ácido tetrahidrofólico, um componente C compreendendo um ou mais suplementos de cálcio, e um componente D compreendendo um ou mais suplementos de magnésio. Os métodos para usar estas composições e composições farmacêuticas para tratar e/ou prevenir osteoporose e/ou doença de junta inflamatória são também descritos.
BR0111210-4A 2000-06-02 2001-05-19 Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias BR0111210A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20857200P 2000-06-02 2000-06-02
PCT/EP2001/005753 WO2001091734A2 (en) 2000-06-02 2001-05-19 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases

Publications (1)

Publication Number Publication Date
BR0111210A true BR0111210A (pt) 2003-12-16

Family

ID=22775091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111210-4A BR0111210A (pt) 2000-06-02 2001-05-19 Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias

Country Status (11)

Country Link
US (1) US6812215B2 (pt)
EP (1) EP1286667B1 (pt)
JP (1) JP2003534373A (pt)
KR (1) KR100814652B1 (pt)
AT (1) ATE329587T1 (pt)
AU (1) AU7566601A (pt)
BR (1) BR0111210A (pt)
CA (1) CA2410885C (pt)
DE (1) DE60120691T2 (pt)
ES (1) ES2266220T3 (pt)
WO (1) WO2001091734A2 (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2433949A1 (en) * 2000-12-14 2002-10-24 Tufts University Compositions and methods for treating an arthritic condition
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
CH696628A5 (de) * 2002-02-26 2007-08-31 Eprova Ag Verwendung von Folaten zur Herstellung einer Zubereitung geeignet zur Vorbeugung und Behandlung von Entzündungen und entzündungsassoziierter Krankheiten, im Speziellen zur Beeinflussung der
US20050215493A1 (en) 2002-05-01 2005-09-29 Masaki Miyake Calcium-containing tissue strengthening agents and use thereof
US7351692B2 (en) 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
US20040048925A1 (en) * 2002-09-09 2004-03-11 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040220266A1 (en) * 2002-09-09 2004-11-04 Wiley David B. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) * 2002-09-17 2004-06-03 Dobbins Thomas A Compositions for the parenteral administration of calcium and magnesium
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
KR20050081595A (ko) * 2004-02-16 2005-08-19 한국 메디텍 제약 주식회사 캄페롤을 유효성분으로 함유하는 골다공증치료제
WO2005096846A1 (en) * 2004-03-11 2005-10-20 Wiley Organics, Inc. Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
RU2268053C1 (ru) * 2004-05-05 2006-01-20 Григорий Николаевич Коныгин Способ лечения гипокальциемий, остеопорозов, переломов
US20070087977A1 (en) * 2004-11-16 2007-04-19 Wendye Robbins Methods and compositions for treating pain
CA2587406A1 (en) * 2004-11-16 2006-05-26 Limerick Neurosciences, Inc. Methods and compositions for treating pain
WO2006079243A1 (fr) * 2005-01-26 2006-08-03 Mian Long Emploi du flavonol et des glycosides de type flavonol dans la stimulation de la croissance des cellules épithéliales rénales tubulaires pour sécréter le facteur de croissance osseuse
EP1879586A1 (en) * 2005-03-10 2008-01-23 Sciele Pharma, Inc. Nutritional preparations comprising folates and essential fatty acids
US20060216361A1 (en) * 2005-03-10 2006-09-28 Edwards John B Compositions and methods for the treatment of osteoporosis and inflammatory joint disease
US20080153831A1 (en) * 2006-10-27 2008-06-26 Sciele Pharma, Inc. Isoflavone-containing compositions for the treatment of osteoporosis and inflammatory joint disease
DE102007029042A1 (de) * 2007-06-21 2008-12-24 Analyticon Discovery Gmbh Pharmazeutische Zusammensetzung mit einem Trihydroxychromenone-Derivate
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
AU2010217238B2 (en) * 2009-02-27 2014-03-06 Council Of Scientific & Industrial Research A controlled release micro-capsule for osteogenic action
HUE032165T2 (en) 2011-04-13 2017-09-28 Thermolife Int Llc Methods of using N-actyl-beta-alanine
EP2799061A1 (en) * 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition containing folates
EP2799060A1 (en) 2013-04-30 2014-11-05 Aprofol AG Stable high dose pharmaceutical composition comprising levoleucovorin
WO2016182262A2 (ko) * 2015-05-14 2016-11-17 주식회사 아모레퍼시픽 관절 기능 향상용 조성물
US20190015448A1 (en) * 2017-07-13 2019-01-17 Summit Innovation Labs LLC Treatment and Prevention of Bone and Joint Disorders
US11007171B2 (en) * 2017-07-13 2021-05-18 Summit Innovation Labs, LLC Treatment and prevention of joint disorders
SG11202006601VA (en) 2018-01-12 2020-08-28 Metimedi Pharmaceuticals Co Ltd Methods of treating chronic inflammatory diseases
BR112021010500A2 (pt) 2018-11-30 2021-08-24 Beth Israel Deaconess Medical Center, Inc. Método para reduzir a p-selectina solúvel em um paciente com câncer, método para reduzir ou prevenir a formação de um trombo em um paciente com câncer, método para promover a regressão tumoral em um paciente com câncer, método para estabilizar ou reduzir o câncer metastático em um paciente com câncer, composição farmacêutica para reduzir a p-selectina solúvel em um paciente com câncer, composição farmacêutica para reduzir ou prevenir a formação de um trombo em um paciente com câncer, composição farmacêutica para promover a regressão tumoral em um paciente com câncer e composição farmacêutica para estabilizar ou reduzir câncer metastático em um paciente com câncer
CN111084780A (zh) * 2020-01-09 2020-05-01 昆明医科大学 老鹳草素在制备治疗骨质疏松合并骨折的药物中的用途
AU2021377897A1 (en) 2020-11-12 2024-09-12 Thermolife International, Llc Methods of increasing blood oxygen saturation
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches
WO2022106410A1 (en) * 2020-11-18 2022-05-27 Société des Produits Nestlé S.A. Compositions and methods using a combination of oleuropein and quercetin for use in cartilage degeneration
JP2024508693A (ja) 2021-02-11 2024-02-28 サーモライフ インターナショナル， エルエルシー 一酸化窒素ガスを投与する方法
JP2022186528A (ja) * 2021-06-04 2022-12-15 セトラスホールディングス株式会社 微粒子水酸化マグネシウムを含む殺菌性組成物及び破骨細胞分化抑制用組成物
GR1011003B (el) * 2024-02-28 2025-07-22 Cloudpharm Private Company, Συμπληρωμα διατροφης για την αντιμετωπιση της απωλειας της οστικης πυκνοτητας (οστεοπενια)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25764A (en) * 1859-10-11 Improvement in cultivators
JPS6416A (en) * 1986-12-23 1989-01-05 Santen Pharmaceut Co Ltd Remedy for arthritis
US5478579A (en) * 1991-02-06 1995-12-26 Biodyn Medical Research, Inc. Method for treatment of osteoporosis
US5807586A (en) * 1996-07-30 1998-09-15 Energetics, Inc. Method of dietary supplementation
JPH10117727A (ja) * 1996-10-16 1998-05-12 Snow Brand Milk Prod Co Ltd ミネラル組成物及びその製造法
JP2000041679A (ja) * 1998-07-31 2000-02-15 Nissho Corp 骨密度の予測方法
EP1121139A1 (en) * 1998-10-19 2001-08-08 MERCK PATENT GmbH Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid
ATE311869T1 (de) * 1998-10-30 2005-12-15 Merck Patent Gmbh Zubereitungen für die behandlung und verhinderung von kardiovaskulären erkrankungen
JP2002187846A (ja) * 2000-10-12 2002-07-05 Nippon Kayaku Co Ltd 組成物及びそれを含有する食品、抗関節炎剤、抗リュウマチ剤又は飼料

Also Published As

Publication number Publication date
US6812215B2 (en) 2004-11-02
WO2001091734A8 (en) 2003-12-18
JP2003534373A (ja) 2003-11-18
AU7566601A (en) 2001-12-11
KR100814652B1 (ko) 2008-03-18
ATE329587T1 (de) 2006-07-15
EP1286667A2 (en) 2003-03-05
CA2410885A1 (en) 2001-12-06
WO2001091734A3 (en) 2002-12-05
DE60120691T2 (de) 2007-06-06
US20030139354A1 (en) 2003-07-24
DE60120691D1 (de) 2006-07-27
ES2266220T3 (es) 2007-03-01
WO2001091734A2 (en) 2001-12-06
KR20040012430A (ko) 2004-02-11
CA2410885C (en) 2010-07-13
EP1286667B1 (en) 2006-06-14

Similar Documents

Publication Publication Date Title
BR0111210A (pt) Composição para o tratamento e/ou prevenção de osteoporose e/ou doenças de juntas inflamatórias
NO20042298L (no) Farmasoytiske preparater og deres anvendelser
SE9901272D0 (sv) New improved formulation
MXPA03004832A (es) Compuestos y sus usos.
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
DK1233770T3 (da) Phosphonatforbindelser
BR0209127A (pt) compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
CL2004000437A1 (es) Compuestos heterociclicos del tipo [1,4]-diazepan-2-ona sustituidos, inhibidores de la enzima dipeptidilpeptidasa-iv (cdp-iv); composicion farmaceutica; y su uso para preparar un medicamento para tratar hiperglucemia, diabetes tipo 2, obesidad, trast
BR0115427A (pt) Composto, composição farmacêutica, métodos para inibir a liberação de peptìdeo beta-amilóide e/ou sua sìntese, para tratar a doença de alzheimer, e para prevenir a doença e o progresso da doença de alzheimer, e, uso de um composto
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
WO2006113864A3 (en) Oxindole compounds and their uses as therapeutic agents
WO2005004803A3 (en) Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer's disease
WO2004062625A3 (en) Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease
EA200501805A1 (ru) Фармацевтическая композиция, содержащая ингибитор фермента дипептидилпептидазы
BR9914044A (pt) ésteres tetrahidropirido
BR0316170A (pt) Combinação, composição farmacêutica, uso de uma combinação, e, método para a profilaxia ou tratamento sinergìstico de câncer
WO2005018545A3 (en) Macrocyclic beta-secretase inhibitors for the treatment of alzheimer's disease
FI20011403A7 (fi) Menetelmä ja koostumukset vatsan sairauksien hoitoon
DK2009025T3 (da) Fremgangsmåde til hæmning af osteoklast-aktivitet
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
WO2004009091A8 (en) Purine derivatives as liver x receptor agonists
GB2340751B (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/0

Ipc: A61K 31/519 (2010.01), A61K 31/7048 (2010.01), A61

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: EUROPEAN BRAND PARTICIPATIONS SA (LU)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.